ARTICLE

FindCenter AddIcon

Psychedelic Support: Bridging Psychedelic Psychotherapy and Epigenetics

By Joseph Tafur — 2019

“Epigenetic changes will be measured after MDMA-assisted psychotherapy in a first of its kind study,” explains Dr. Joe Tafur about a research collaboration with MAPS investigators, the Modern Spirit research team, and the University of Southern California, Department of Psychiatry. The study will investigate ways MDMA-assisted psychotherapy may lead to measurable biochemical (“epigenetic”) change.

Read on maps.org

FindCenter Post-Image

How Researchers and Advocates of Color Are Forging Their Own Paths in Psychedelic-Assisted Therapy

We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.

Article
Steph Yin
2020
FindCenter AddIcon
FindCenter Post-Image

Who Will Benefit From Psychedelic Medicine?

These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.

Article
Whitney Joiner
2020
FindCenter AddIcon
FindCenter Post-Image

The Cost of Exclusion in Psychedelic Research

In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.

Article
Xinyuan Chen, Mackenzie Bullard, Christy Duan, Jamilah R. George, Terence Ching, Stephanie Kilpatrick, Jordan Sloshower, Monnica Williams
2020
FindCenter AddIcon
FindCenter Post-Image

Psychedelic Psychotherapy Is Coming: Who Will Be Included?

A new study finds widespread exclusion of minorities in psychedelic research.

Article
Monnica T. Williams
2018
FindCenter AddIcon
FindCenter Post-Image

Study Finds Ketamine Can Help Patients Manage Depression and PTSD

Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.

Article
Hannah Sabourin
2021
FindCenter AddIcon
FindCenter Post-Image

A Psychedelic Drug Passes Big Test for PTSD Treatment

In an important step toward medical approval, MDMA, the illegal drug popularly known as Ecstasy or Molly, was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired with talk therapy.

Article
Rachel Nuwer
2021
FindCenter AddIcon
FindCenter Post-Image

Psychedelics and Race: A Profile of Dr. Monnica T. Williams

The exuberant “renaissance” of studies researching psychedelic-assisted psychotherapy in the past twenty years has not sufficiently included the enrollment of racially diverse participants, a problem that psychedelic science and clinical research shares with mainstream psychiatry

Article
Patricia Kubala
2020
FindCenter AddIcon
FindCenter Post-Image

MDMA-Assisted Couples Therapy: How a Psychedelic Is Enhancing Intimacy and Healing PTSD

Research over the last decade has shown MDMA-assisted psychotherapy to be effective in treating PTSD from military combat, sexual assault and childhood abuse. Now researchers are trialing MDMA with couples and finding promising results.

Article
Anne Wagner
2019
FindCenter AddIcon
FindCenter Post-Image

Psychedelic Drugs Can Help Treat PTSD Caused by Racism, Discrimination: Researchers

Williams is the co-lead author of a recent retrospective study that found those who tried doses of psilocybin (more commonly known as magic mushrooms), LSD, or MDMA (the pure substance found in Ecstasy or Molly) reported a decrease in trauma symptoms, depression and anxiety after 30 days.

Article
Avis Favaro, Elizabeth St. Philip, Solarina Ho
2021
FindCenter AddIcon
FindCenter Post-Image

MDMA Lauded as ‘Breakthrough’ Therapy for PTSD Patients

The Food and Drug Administration (FDA) has approved the design of two Phase 3 clinical trials of MDMA for treating PTSD, according to the Multidisciplinary Association for Psychedelic Studies (MAPS), which is funding and leading the clinical trials.

Article
Maureen Meehan
2017
FindCenter AddIcon

EXPLORE TOPIC

Epigenetics